A detailed history of Vantage Consulting Group Inc transactions in Fibrogen Inc stock. As of the latest transaction made, Vantage Consulting Group Inc holds 195,707 shares of FGEN stock, worth $66,540. This represents 1.01% of its overall portfolio holdings.

Number of Shares
195,707
Previous 195,707 -0.0%
Holding current value
$66,540
Previous $174,000 55.17%
% of portfolio
1.01%
Previous 0.28%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 11, 2023

SELL
$2.49 - $20.59 $239,040 - $1.98 Million
-96,000 Reduced 32.91%
195,707 $528,000
Q1 2023

May 10, 2023

SELL
$15.95 - $25.18 $5.01 Million - $7.91 Million
-314,006 Reduced 51.84%
291,707 $5.44 Million
Q2 2022

Aug 09, 2022

BUY
$7.94 - $12.96 $4,287 - $6,998
540 Added 0.09%
605,713 $6.4 Million
Q1 2022

May 16, 2022

SELL
$12.02 - $16.79 $6,490 - $9,066
-540 Reduced 0.09%
605,173 $7.28 Million
Q4 2020

Feb 12, 2021

BUY
$37.09 - $48.97 $22.5 Million - $29.7 Million
605,713 New
605,713 $22.5 Million

Others Institutions Holding FGEN

About FIBROGEN INC


  • Ticker FGEN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 93,741,200
  • Market Cap $31.9M
  • Description
  • FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...
More about FGEN
Track This Portfolio

Track Vantage Consulting Group Inc Portfolio

Follow Vantage Consulting Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vantage Consulting Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vantage Consulting Group Inc with notifications on news.